DRL's generic version of Zofran likely to generate Rs 200 cr in 6 months

Dr Reddy’s Labs’ (DRL) generic version of GlaxoSmithKline’s (GSK) Zofran could generate revenues of around Rs 200 crore ($45 million) in the US in the six-month exclusivity period.